Researchers from the Institute for Molecular Bioscience (IMB) have made advances in understanding the cellular processes that occur during wound healing, skin cancer, and inflammatory skin conditions such as psoriasis.
Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
Researchers from The University of Queensland’s Institute for Molecular Bioscience have uncovered a secret of an immune cell on the frontline that could assist with developing new treatments for inflammatory diseases.
University of Queensland researchers have discovered how an important pair of molecules—found within the cells of our immune system—team up to help ‘switch off’ inflammation in the body.